ESC 2023 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
European Society of Cardiology｜循環器 / 心不全・心筋疾患｜13 ページ｜チャンク 139｜推奨 7 件｜superseded
推奨表（自動抽出）
PDF の推奨表から機械的に抽出したものです。引用前に必ず該当ページの原文を確認してください。
| 頁 | クラス | レベル | 推奨文 | 表 |
|---|---|---|---|---|
| p.7 | I | A | An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with HFmrEF to reduce the risk of HF hospitalization or CV death.c 6,8 | Recommendation Table 1 — Recommendation for the treatment of patients with symptomatic heart failure with mildly reduced ejection fraction |
| p.7 | I | A | © ESC 2023 An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with HFpEF to reduce the risk of HF hospitalization or CV death.c 6,8 | Recommendation Table 2 — Recommendation for the treatment of patients with symptomatic heart failure with preserved ejection fraction |
| p.9 | I | B | An intensive strategy of initiation and rapid up-titration of evidence-based treatment before discharge and during frequent and careful follow-up visits in the first 6 weeks following a HF hospitalization is recommended to reduce the risk of HF rehospitalization or death.c,d,e 16 | Recommendation Table 3 — Recommendation for pre-discharge and early post-discharge follow-up of patients hospitalized for acute heart failure |
| p.10 | I | A | In patients with T2DM and CKD,c SGLT2 inhibitors are recommended to reduce the risk of HF hospitalization or CV death.35 | Recommendation Table 4 — Recommendations for the prevention of heart failure in patients with type 2 diabetes mellitus and chronic kidney disease |
| p.10 | I | A | In patients with T2DM and CKD,c finerenone is recommended to reduce the risk of HF hospitalization.10,11,34,40 | Recommendation Table 4 — Recommendations for the prevention of heart failure in patients with type 2 diabetes mellitus and chronic kidney disease |
| p.11 | I | A | Intravenous iron supplementation is recommended in symptomatic patients with HFrEF and HFmrEF, and iron deficiency, to alleviate HF symptoms and improve quality of life.c 12,41,47–49 | Recommendation Table 5 — Recommendations for the management of iron deficiency in patients with heart failure |
| p.11 | IIa | A | Intravenous iron supplementation with ferric carboxymaltose or ferric derisomaltose should be considered in symptomatic patients with HFrEF and HFmrEF, and iron deficiency, to reduce the risk of HF hospitalization.c 12,41,43–46 | Recommendation Table 5 — Recommendations for the management of iron deficiency in patients with heart failure |